Scancell completes up to US$25 million in debt financing, providing optionality alongside equity investment to finance iSCIB1+ phase 3 development
Neuphoria Therapeutics Inc NEUP
$3.57
▼ -2.19%
($-0.08)
🎈 Low Float
Open
$3.64
Prev Close
$3.65
Day Range
$3.57 – $3.65
52W Range
$3.19 – $21.40
Market Cap
$19.32M
Beta
0.76
EPS (TTM)
$-5.00
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1999-12-21 |
| Shares Out. | 5,400,000 |
| Website | neuphoriatx.com/ ↗ |
| Employees | 1 |
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.
Neuphoria Therapeutics Inc is a publicly traded company under the ticker symbol NEUP on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
6 analysts (2026-09-01)